Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer.

Sait OzturkDeepti MathurRoyce W ZhouDavid MulhollandRamon E Parsons

Published in: Prostate cancer and prostatic diseases (2020)

Our work highlights that synthetic lethality arises upon the combination of PTEN loss and leflunomide treatment in prostate cancer, and may present a therapeutic opportunity for this patient population.

Keyphrases

prostate cancer
radical prostatectomy
cell proliferation
pi k akt
case report
signaling pathway
replacement therapy
smoking cessation